Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 3:15 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,757 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorders Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
View directory record Official record
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 3, 2026, 3:15 AM EST
Enrolling by invitation No phase listed Observational

Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements

NCT06002100
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
fNIRS measurement
Other
Lead sponsor
Kernel
Industry
Eligibility
18 Years to 75 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Costa Mesa, California • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 3 Interventional

Predictors of Depression Treatment Response to Exercise

NCT02583867
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 2 Interventional Results available

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

NCT03559192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-67953964, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Nov 3, 2026, 3:15 AM EST
Terminated Phase 2 Interventional Results available

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

NCT01145755
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 2 Interventional Results available

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

NCT05686408
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major, Depressive Episode, Depression Severe
Interventions
TNX-601 ER, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Little Rock, Arkansas • Bellflower, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Nov 3, 2026, 3:15 AM EST
Withdrawn Phase 4 Interventional

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

NCT02028026
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety, Comorbidity
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 2Phase 3 Interventional

A Stepped Care Model of Adolescent Depression Treatment in Primary Care

NCT01443715
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
Stepped Care IPT-A (SCIPT-A), Treatment as Usual
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 20 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 2 Interventional Results available

Rapid Antidepressant Effects of Yohimbine in Major Depression

NCT00078715
View directory record Official record
Conditions
Depression, Involutional, Major Depresssion
Interventions
Yohimbine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Nov 3, 2026, 3:15 AM EST
Recruiting Not applicable Interventional

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder

NCT07282678
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions
Closed-loop tACS, Sham Comparator
Device
Lead sponsor
Pulvinar Neuro, LLC
Industry
Eligibility
22 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 3:15 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2026

NCT07685925
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 3, 2026, 3:15 AM EST
Completed No phase listed Observational Accepts healthy volunteers

p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram

NCT00697268
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 3, 2026, 3:15 AM EST
Terminated Not applicable Interventional

Pharmacogenomic Testing in Major Depressive Disorder

NCT03228953
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pharmacogenomic testing
Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 3, 2026, 3:15 AM EST
Completed Not applicable Interventional

Multifaceted Depression and Cardiovascular Program

NCT02069912
View directory record Official record
Conditions
Depression, Depressive Disorder, Behavioral Symptoms, Mood Disorders
Interventions
Collaborative depression care management
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 3 Interventional

A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior

NCT01447602
View directory record Official record
Conditions
Unipolar Depression, Dysthymia
Interventions
IPT-A
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

NCT01250873
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Nov 3, 2026, 3:15 AM EST
Terminated Not applicable Interventional Results available

Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression

NCT06219681
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Active neurofeedback, Sham neurofeedback
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 3, 2026, 3:15 AM EST
Not listed Not applicable Interventional

Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression

NCT01694719
View directory record Official record
Conditions
Depression
Interventions
Brief Behavioral Activation Treatment for Depression, Cognitive Control Training
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Nov 3, 2026, 3:15 AM EST
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

NCT04103892
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
CLE-100, placebo
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
45
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 3, 2026, 3:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Tai Chi Training for Treating Depressed Chinese Americans

NCT01263730
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tai Chi
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Nov 3, 2026, 3:15 AM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool

NCT07280065
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder
Interventions
Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version
Device · Behavioral
Lead sponsor
Senseye, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
5
States / cities
Aurora, Colorado • Savannah, Georgia • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 3, 2026, 3:15 AM EST
Completed Not applicable Interventional

Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers

NCT02122068
View directory record Official record
Conditions
Mentalizing Imagery Therapy, Relaxation Recording
Interventions
Mentalizing Imagery Therapy, Relaxation cd
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Nov 3, 2026, 3:15 AM EST